3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Recurrence
4
Ovarian Neoplasms
4
Glioblastoma
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Radiation Pneumonitis
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Fallopian Tube Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Rectal Neoplasms
1
Patients With Any Advanced Solid Tumors
1
Pancreatic Neoplasms
1
Ovarian Diseases
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Mesothelioma, Malignant
1
Melanoma, Cutaneous Malignant
1
Lymphangioleiomyomatosis
1
Inflammatory Breast Neoplasms
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Esophagogastric Adenocarcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Interventions
Carboplatin
31
Pemetrexed
28
Radiotherapy
22
Bevacizumab
21
Cisplatin
20
Gemcitabine
18
Paclitaxel
17
Erlotinib Hydrochloride
15
Docetaxel
12
Gefitinib
8
Nivolumab
6
Mastectomy, Segmental
6
Magnetic Resonance Spectroscopy
6
pembrolizumab
5
aflutinib
5
Radiosurgery
5
tislelizumab
4
Vinorelbine
4
Surgical Procedures, Operative
4
Specimen Handling
4
Sorafenib
4
Platinum
4
Metformin
4
Biopsy
4
2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a
4
sargramostim
3
apatinib
3
Taxes
3
Cetuximab
3
Anterior Temporal Lobectomy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma of Lung
×
nintedanib
×
Clear all
NCT03361319
2020-11-24
N3
Royal Marsden NHS Foundation Trust
Phase 1/2
Withdrawn